- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03002064
Docetaxol Plus Cisplatin Versus 5-Fu Plus Cisplatin as 1st-line Chemotherapy in Advanced ESCC Patients
Docetaxel Plus Cisplatin Versus 5-fluorouracil Plus Cisplatin as First-line Treatment for Metastatic Esophageal Squamous Patients: a Prospective Multicenter, Randomized Controlled Clinical Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Esophageal cancer is the 6th most common cause of cancer deaths worldwide and it is an endemic in many parts of the world, particularly in the developing countries, including China. Histologically, esophageal cancer can be classified as adenocarcinoma and esophageal squamous cell. carcinoma (ESCC) which is the most common histology in Asia. For locally advanced or metastatic ESCC patients, chemotherapy can improve overall survival (OS) and progression free survival (PFS). There is no standard first-line chemotherapy for ESCC patients. Cisplatin (DDP) plus fluorouracil is the most common used combination with a response rate of 25-35%. Previous studies showed that the combination of paclitaxel with cisplatin had good tolerance and efficacy to esophageal carcinoma. This is a prospective randomized control phase III clinical trial to compare the efficacy and safety between docetaxel/cisplatin and 5-Fu/cisplatin as the 1st line treatment in advanced or metastatic esophageal carcinoma patients.
Sample size:
This is a non-inferior study. The planned sample size was 358 patients, allowing for a 10% dropout rate and assuming the median progression free survival was 5.5 months in the experimental group and 4 months in the control group with a hazard ratio of 0.727, α=0.05, β=0.2. The planned enrolled time was 36 months and 12 months of follow up. The ratio between control and experimental group is 1:1.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Miao-Zhen Qiu, MD, PhD
- Phone Number: 86-020-87342490
- Email: qiumzh@sysucc.org.cn
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- Recruiting
- Cancer center of Sun Yat-sen University
-
Sub-Investigator:
- Miao-zhen Qiu, MD
-
Contact:
- Miao-Zhen Qiu, MD, PhD
- Phone Number: 86-020-87342490
- Email: qiumzh@sysucc.org.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must give written informed consent signed voluntarily by patients themselves or their supervisors witted by doctors.
- Patients must have histologically confirmed esophageal squamous cell carcinoma without prior treatments including surgery, chemotherapy, radiotherapy, and targeting treatment. Patients were allowed to have palliative radiotherapy 3 months before the enrollment and the target lesions should not be within the radiotherapy region. The last date of adjuvant therapy should be over 6 months before the enrollment.
- With measurable or evaluable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
- With an expected life expectancy of ≥ 3 months.
- With a performance status of 0-1 on the Eastern Cooperative Oncology Group (ECOG) scale.
- Without serious system dysfunction and could tolerate chemotherapy.
- Patients must have normal bone marrow function with a hemoglobin (HGB) of ≥90g/L, an white blood cell (WBC) counts of ≥4.0×10^9/L,a neutrophil count of ≥2.0×10^9/L, , a platelet count of ≥100×10^9/L.
- Patients must have normal liver and renal function with a total bilirubin (TBil) of ≤1.5 upper normal limitation (UNL), a creatinine (Cr) of ≤ 1.0 UNL, alanine aminotransferase (ALAT) and aspartate aminotransferase (ASAT) of ≤2.5 UNL.
- Patients must have normal electrocardiogram results and no history of congestive heart failure.
- Women of childbearing age should voluntarily take contraceptive measures. Without drug addition
- Patients must be with good compliance and agree to accept follow-up of disease progression and adverse events.
Exclusion Criteria:
- Allergic to known drug
- Patients who have received prior treatment including chemotherapy, radiotherapy and surgery for the advanced or metastatic diseases.
- Receive docetaxel within 6 months as adjuvant or neoadjuvant chemotherapy.
- Brain metastasis.
- Without measurable or evaluable disease.
- With history of other tumors except for those of cervical carcinoma in situ or skin basal cell carcinoma who had been completely treated and without relapse in last 5 years.
- With serious diseases such as congestive heart failure, uncontrolled myocardial infarction and arrhythmia, liver failure and renal failure.
- With neurological or psychiatric abnormalities that affect cognitive.
- Pregnant or lactated women (premenopausal women must give urine pregnancy test before enrollment)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DP group
Docetaxel plus cisplatin.
Docetaxel: 60mg per square metre on day 1 and Cisplatin: 60mg per square metre on day 1, repeated every 3 weeks till progression or at most 6 cycles.
|
60mg per square metre on day 1, repeated every 3 weeks till progression or at most 6 cycles.
Other Names:
Cisplatin: 60mg per square metre on day 1, repeated every 3 weeks till progression or at most 6 cycles
Other Names:
|
Active Comparator: PF group
Cisplatin plus 5-fluorouracil.
Cisplatin: 60mg per square metre on day 1 and 5-fluorouracil 3750mg per square metre, civ 120 hours every 3 weeks till progression or at most 6 cycles.
|
Cisplatin: 60mg per square metre on day 1, repeated every 3 weeks till progression or at most 6 cycles
Other Names:
5-fluorouracil 3750mg per square metre, civ 120 hours every 3 weeks till progression or at most 6 cycles
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free survival
Time Frame: 36 months
|
From the date of randomization until the date of first documented relapse of disease or date of death from any cause, whichever came first
|
36 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: 36 months
|
From the date of randomization until the date of death from any cause.
|
36 months
|
Response rate
Time Frame: 36 months
|
Including complete response and partial response
|
36 months
|
Grade 3 and 4 toxicities
Time Frame: 36 months
|
According to the CTCAE
|
36 months
|
Quality of life--Score of the questionnaire
Time Frame: 36 months
|
EORTC QLQ-C30 and QLQ-OES18 questionnaire.
|
36 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Rui-hua Xu, MD, PhD, Sun Yat-sen University
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Head and Neck Neoplasms
- Esophageal Diseases
- Esophageal Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Docetaxel
- Cisplatin
- Fluorouracil
Other Study ID Numbers
- SYSUCC-ESO-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Esophagus Cancer
-
Mayo ClinicFred Hutchinson Cancer CenterCompletedBarrett's Esophagus With High Grade Dsyplasia | Early Esophageal CancerUnited States
-
University of Alabama at BirminghamAventis Pharmaceuticals; Pharmacia and UpjohnCompletedEsophageal Cancer | Cancer of the Esophagus | Esophageal Neoplasm | Esophagus Cancer | Cancer of EsophagusUnited States
-
University Hospitals, LeicesterNational Institute for Health Research, United Kingdom; University of LeicesterCompletedBarretts Esophagus | Esophageal High-Grade Intraepithelial Neoplasia | Esophageal Cancer Stage IUnited Kingdom
-
University Medical Center GroningenCompletedEsophageal Cancer | Barrett Esophagus | Dysplasia in Barrett EsophagusNetherlands
-
Academisch Medisch Centrum - Universiteit van Amsterdam...University Medical Center Groningen; UMC Utrecht; Erasmus Medical Center; Catharina... and other collaboratorsNot yet recruitingEsophageal Cancer | Barrett Adenocarcinoma | Barretts Esophagus With Dysplasia
-
Johns Hopkins UniversityAmerican Society for Gastrointestinal Endoscopy; Pentax Medical CorporationCompletedBarrett's Esophagus, Esophageal Intraepithelial NeoplasiaUnited States, Germany
-
City of Hope Medical CenterRecruitingEsophageal Cancer | Esophageal Neoplasms | Gastroesophageal Reflux | Barrett Esophagus | Esophageal Adenocarcinoma | Reflux Disease | Barretts Esophagus With High Grade Dysplasia | Barrett Adenocarcinoma | Esophagus Cancer | Barrett's Esophagus Without Dysplasia | Barretts Esophagus With Dysplasia | Esophagus... and other conditionsUnited States
-
Mayo ClinicWithdrawnEsophageal Cancer | Cancer of the Esophagus | Esophagus Cancer | Cancer of Esophagus | Esophagus Neoplasm | Neoplasms, EsophagealUnited States
-
Pentax MedicalCompletedEsophageal Cancer | Barrett's EsophagusUnited States, Netherlands
-
University of Colorado, DenverUniversity of California, Los Angeles; H. Lee Moffitt Cancer Center and Research... and other collaboratorsRecruitingTREAT-BE Study (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus)Esophageal Cancer | Barrett's EsophagusUnited States
Clinical Trials on Docetaxel
-
Nereus Pharmaceuticals, Inc.CompletedCancerUnited States, Australia, India, Chile, Brazil, Argentina
-
Zhuhai Beihai Biotech Co., LtdCompletedSolid Tumours | Bioequivalence | DocetaxelIndia
-
Jiangsu HengRui Medicine Co., Ltd.Shanghai Pulmonary Hospital, Shanghai, ChinaCompletedNon-Small Cell Lung Cancer (NSCLC)China
-
Tianjin Medical University Cancer Institute and...Recruiting
-
National Cancer Center, KoreaSeoul National University Bundang Hospital; Gachon University Gil Medical Center and other collaboratorsUnknownGastric CancerKorea, Republic of
-
Optimal Health ResearchCompletedBreast Cancer | Lung Cancer | Prostate CancerUnited States
-
Arog Pharmaceuticals, Inc.WithdrawnCarcinoma, Non-Small-Cell Lung
-
Boehringer IngelheimCompletedCarcinoma, Non-Small-Cell LungJapan
-
SanofiCompleted
-
SanofiCompletedLung NeoplasmsFrance, Netherlands, Spain, Turkey, Belgium, Finland, Italy, United Kingdom